Jeonjinbio Co. Ltd
Jeonjinbio Co., Ltd. develops and produces natural bio-pesticides, alternative chemical products, and other biotechnology products. The company offers repellent for bird, boar, rodent, snake, and sea lice; and dress perfume, including Paris 16e, Paris 16e Bouquet, Bouquet Garni, and Bridcan, as well as mosquito repellent. It also provides laundry products. Jeonjin Bio Co., Ltd. was founded in 200… Read more
Jeonjinbio Co. Ltd (110020) - Total Liabilities
Latest total liabilities as of September 2025: ₩1.27 Billion KRW
Based on the latest financial reports, Jeonjinbio Co. Ltd (110020) has total liabilities worth ₩1.27 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jeonjinbio Co. Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how Jeonjinbio Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Jeonjinbio Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Jeonjinbio Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chuang's China Investments Limited
F:CUG
|
Germany | €499.00 Million |
|
Signal Advance Inc
PINK:SIGL
|
USA | $3.93K |
|
Sun Peak Metals Corp
OTCQB:SUNPF
|
USA | $47.14K |
|
SaintMed Public Company Limited
BK:SMD
|
Thailand | ฿396.45 Million |
|
Enwell Energy plc
PINK:RGPMF
|
USA | $18.87 Million |
|
Seni Jaya Corporation Bhd
KLSE:9431
|
Malaysia | RM74.37 Million |
|
FibroBiologics, Inc. Common Stock
NASDAQ:FBLG
|
USA | $8.62 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Jeonjinbio Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jeonjinbio Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jeonjinbio Co. Ltd (2015–2024)
The table below shows the annual total liabilities of Jeonjinbio Co. Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩1.19 Billion | -89.62% |
| 2023-12-31 | ₩11.48 Billion | +37.39% |
| 2022-12-31 | ₩8.36 Billion | -40.38% |
| 2021-12-31 | ₩14.02 Billion | +89.15% |
| 2020-12-31 | ₩7.41 Billion | +111.04% |
| 2019-12-31 | ₩3.51 Billion | +9.45% |
| 2018-12-31 | ₩3.21 Billion | -16.15% |
| 2017-12-31 | ₩3.83 Billion | +7.86% |
| 2016-12-31 | ₩3.55 Billion | -55.35% |
| 2015-12-31 | ₩7.95 Billion | -- |